Healthcare / Medical DevicesShanghai
$16.73
+0.24 (+1.42%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $10.6M · quality 51.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
37/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.3B
P/E
167.3x
↑EV/EBITDA
60.2x
↑ROE
1.0%
↑Gross Margin
68.7%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-3.0%
FCF CAGR
-42.9%
FCF margin
4.7%
FCF / Net income
0.76x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $223.7M · net income $13.8M · FCF $10.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $223.7M | $223.7M | $206.0M | $226.5M | $245.3M |
| Net Income | $13.8M | $13.8M | $-12.7M | $54.2M | $95.2M |
| EBITDA | $36.4M | $36.4M | $12.4M | $70.3M | $116.1M |
| EPS | 0.10 | 0.10 | -0.09 | 0.41 | 0.71 |
| Gross Margin | 68.7% | 68.7% | 71.1% | 82.7% | 83.4% |
| Operating Margin | -1.7% | -1.7% | -8.4% | 14.5% | 33.9% |
| Net Margin | 6.2% | 6.2% | -6.1% | 23.9% | 38.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.04 | 0.04 | 0.05 |
| Current Ratio | 53.20 | 53.20 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $10.6M | $10.6M | $-33.0M | $29.8M | $56.6M |
| Returns | |||||
| ROE | 1.0% | 1.0% | -0.9% | 3.9% | 7.3% |
| Valuation | |||||
| P/E | 167.30 | 167.30 | — | 52.22 | 33.46 |
| EV/EBITDA | 60.22 | 60.22 | 184.55 | 38.77 | 25.74 |
| P/B | 1.61 | 1.61 | 1.70 | 2.05 | 2.45 |
| Growth & Yield | |||||
| Revenue Growth | 8.6% | 8.6% | -9.0% | -7.7% | — |
| EPS Growth | 211.1% | 211.1% | -122.0% | -42.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
145.8%
EPS terminal req.
$1.48
Spread vs growth
65.3%
5Y implied EPS CAGR
78.2%
EPS terminal req.
$1.80
Spread vs growth
132.9%
10Y implied EPS CAGR
40.0%
EPS terminal req.
$2.89
Spread vs growth
171.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+1.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.09 → 0.10
Residual
+1.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.